Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42

Fig. 3

Effect of amyloid-β 1–42 peptide (Aβ42) spiking and incubation in individual subjects (Alzheimer’s disease [AD] and healthy normal control subjects). Each sample was incubated under the indicated conditions. To measure amyloid-β oligomers, a multimer detection system (MDS) assay was used. (a1) 0 ng/ml Aβ42 at 0 h, (a2) 0 ng/ml Aβ42 at 144 h, (b1) 10 ng/ml Aβ42 at 0 h, and (b2) 10 ng/ml Aβ42 at 144 h. (c) Dynamic changes of Aβ42 incubation in individual subjects at 72 h and 144 h. Each sample was incubated for 72 h and 144 h after being spiked with 10 ng/ml Aβ42 and measured by MDS. *p < 0.05; ** p < 0.01. RLU Relative luminescence units

Back to article page